Out of the Lab: Operationalizing Cell and Gene Therapy

Nicholas (Nico) Crudele
  • 0.0 (0)
  • Medicine

In Cell & Gene Therapy, opportunity created by openly discussing operational reality far outweighs the micro-risk of looking unpolished. By building a safe, unscripted space where experts can talk naturally about real work, we stop pretending everything is fine and start building the solutions needed to actually fix the system. Explore our Solution: https://www.methodmade.ca/?utm_source=podcast&utm_medium=show_notes&utm_campaign=out_of_the_lab

  1. 4d ago

    Bunny Suits, Ice Buckets, and Slashing COGS: Bridging R&D and GMP Realities with Jerry (CellBri)

    Why do brilliant R&D processes stall or fail when transferred into a GMP cleanroom? In this episode of Out of the Lab, host Nicholas Crudele sits down with Jerry from CellBri to unpack the unspoken assumptions, technical miscommunications, and equipment hurdles that delay cell therapy manufacturing. From the reality of using ice buckets instead of precise 4°C incubation to reducing batch COGS from $150,000 down to under $20,000 using flexible automation, Jerry breaks down how effective communication through documentation and smart software UX de-risk cell therapy scale-up. Key Topics Covered: The R&D vs. Cleanroom Disconnect: Why gowning, double-gloving, and workflow timing ruin unexamined bench protocols during tech transfer. The "Oral Tradition" Trap: How minor miscommunications (0°C vs. 4°C) can cause month-long troubleshooting investigations. Slashing COGS with Flexible Automation: How modern automated systems dramatically cut labor costs and production days. UX in the Cleanroom: Replacing ambiguous error codes with on-screen video guidance to prevent catastrophic batch losses.

  2. Sep 8

    Beyond Manufacturing: Why Portal Fatigue and Physician Adoption Are Blocking Cell Therapy Access

    Is manufacturing complexity really the main bottleneck holding back cell and gene therapies, or are we ignoring the operational friction occurring right at the physician's desk? In this episode of Out of the Lab, host Nicholas Crudele sits down with Carl Schoellhammer, Partner at DeciBio, to discuss why the cell therapy industry must shift its focus from cleanroom COGS to physician awareness, simplified prescribing workflows, and clinical adoption. Carl shares his perspective on the barriers stalling patient access, comparing centralized US logistics with Europe’s decentralized hospital exemption framework and explaining why the key to scaling cell therapies lies in streamlining the entire prescribing journey. Key Takeaways: The Manufacturing Fallacy: Why COGS and production complexity are no longer the primary bottlenecks limiting cell therapy scale. Portal Fatigue: How fragmented drug scheduling systems force doctors to hunt for passwords on Post-it notes just to write a script. The European Exemption Model: How centers like Hospital Clínic de Barcelona are leveraging hospital exemption acts to dose over 500 patients in-house. Solving Logistics: Easing the administrative and travel burdens on non-metropolitan patients. Predictive Operations: How automated analytics and process monitoring can drastically lower batch failure rates.

  3. Sep 1

    The End of the Supply Chain Is the Patient: Shortages, Governance, and Risk with Dr. Angeliki Kotsianti

    What happens when a biopharma supply chain breaks upstream from the clinic? It doesn't just delay manufacturing, it forces doctors at the bedside to choose which patients receive curative therapy and which ones have to wait. In this episode of Out of the Lab, host Nicholas Crudele sits down with Dr. Angeliki Kotsianti, founder and scientific advisor of Oncolyze and former Senior Global Medical Benefit Risk Lead at Pfizer. Drawing on her unique perspective as both a treating physician and a senior biopharma executive, Angeliki breaks down why drug shortages must be re-framed as clinical events, how evolving regulatory guidance (like Computer Software Assurance) demands human medical judgment, and why operational governance must be engineered into drug development from day one. Key Takeaways: The Bedside Realities of Shortages: Lessons from the 2009 oncology supply chain crisis and why single-source dependencies leave zero buffer for clinical delivery. Shortage as a Clinical Event: How manufacturing line downtime, API consolidation, and quality deviations directly impact medical choices and patient survival. Human Accountability vs. Automation: Why software tools cannot take management decisions or replace clinical judgment when evaluating patient exposure. Designing the Line from the Outset: Why operationalizing advanced therapies requires one owner across the entire pathway from bench to patient.

  4. Aug 25

    Global Competition, Tech Transfer Traps, and Cost Reduction Realities with Alfred Sloan

    In this episode of Out of the Lab, host Nico sits down with 20-year cell and gene therapy expert Alfred Sloan to dissect the operational and capital constraints facing advanced therapy development today. From the pressure to rapidly accelerate clinical timelines to the rising threat of global competition outcasting domestic manufacturing costs, Alfred breaks down why the industry must shift from isolated IP retention to scalable, repeatable manufacturing frameworks. Key Discussion Points: The Scalability Gap: Why existing technologies fail to scale seamlessly from research to commercial production. Global Competition & Medical Tourism: How overseas government subsidies and collaborative models threaten to outpace US manufacturing within five years. Tech Transfer Traps: Why handing over a paper SOP to a CDMO leads to $100,000 run failures and how continuous technical support bridges the gap. Operational Cost Reduction: Navigating master service agreements, expediting fees, modular "widget" approaches, and standardizing assembly-line manufacturing. Timestamps: 00:01:25 – Capital Constraints and Clinical Acceleration 00:03:27 – The Scalability Bottleneck Across Development Stages 00:06:28 – Breaking Down Knowledge Sharing and IP Barriers 00:11:36 – Global Competition, Government Subsidies, and Medical Tourism 00:16:43 – Operational Cost Reduction: Vendor Lock-In, Expediting Fees, and Modular Systems 00:20:50 – Tech Transfer Realities: The Limits of Paper SOPs and Scaling Microliters to Liters 00:26:26 – Asset Acquisition vs. Building from Scratch 00:33:27 – Supply Chain Vulnerabilities, Reagent Shortages, and Modular Platforms

  5. Aug 18

    Designing for Resilience: Why CGT Supply Chain Begins Years Before Tech Transfer | Mehran Bhatti

    How do 1 in 16 cell and gene therapies fail, not because of the biology, but because of the supply chain? In this episode of Out of the Lab, host Nico sits down with Mehran, a seasoned Cell & Gene Therapy supply chain consultant, to dissect why operational resilience must be engineered into your product long before tech transfer ever takes place. From CDMO selection gaps to un-addressable spend and non-standard Bill of Materials (BOM) choices, Mehran exposes the hidden operational traps that trigger FDA Complete Response Letters (CRLs) and derail launches. In this episode, we cover: Who Owns Resilience? Why supply chain expertise must intersect with early CMC and process development. The CDMO Bottleneck: Unpacking why 40% of manufacturing-related FDA hurdles stem from partner selection and process optimization gaps. Addressable vs. Non-Addressable Spend: Why 42% of materials get locked in filings and how to optimize raw material selection up front. Real-World Harmonization: Lessons from J&J’s Carvykti pipeline on managing apheresis variability and standardizing network supply. The Future of Orchestration: How AI and predictive analytics are transforming patient slotting, scheduling, and apheresis quality. Timestamps & Chapters: 00:00 – Introduction: Supply chain resilience in Cell & Gene Therapy 02:03 – Who owns resilience? Bridging CMC, process development, and supply chain 04:57 – CDMO partner selection & commercial readiness 06:21 – The cost of failure: CRLs, manufacturing quality, and CDMO gaps 08:05 – Process ownership vs. CDMO lock-in: Lessons from J&J and apheresis 12:21 – Addressable vs. non-addressable spend in biomanufacturing 16:38 – The 50 mL Syringe Example: Why process engineers need supply chain optics 20:15 – Geopolitical risk, tariffs, and global facility harmonization 24:18 – Built-in network resilience: Lessons from radiopharmaceuticals 28:20 – Logistics, cold-chain, and patient orchestration in Europe vs. US 34:34 – The role of data, AI, and predictive analytics in apheresis quality

  6. Aug 11

    You Can’t Test Quality Into a Product: FDA Import Alerts & GXP with Wynngate Consulting

    What happens when a foreign manufacturer gets put on an FDA import alert? Or when a single undocumented ingredient turns a harmless dietary supplement into an unapproved drug? In this episode of Out of the Lab, host Nico sits down with Dan and Binh from Wynngate Consulting. Bringing decades of insider FDA experience from compliance enforcement to foreign facility inspections, they pull back the curtain on the operational realities of GXP manufacturing. We explore the massive regulatory shifts brought on by the Food Safety Modernization Act (FSMA) and why the FDA's Foreign Supplier Verification Program has changed the game for importers. In this episode, we cover: The Overlapping 50%: The surprising similarities and critical differences between dietary supplement GMPs (Part 111) and pharmaceutical GMPs (Part 211). The "Checking the Box" Trap: How an inadequate response to an FDA 483 observation can escalate into an Import Alert and a 10-year remediation nightmare. Intentional vs. Accidental Adulteration: From shared line cross-contamination to companies secretly lacing weight-loss supplements with active pharmaceuticals to dodge clinical trials. The Old FDA Adage: Why you can never test quality into a product once underlying GMP violations exist. Supply Chain Resilience: Why vetting your foreign CDMO's quality management system is the ultimate risk mitigation technique for drug sponsors. Dan and Binh consult on GxP compliance at Wynngate Consulting.Connect with them: Dan Simonsen, Vice President: https://www.linkedin.com/in/danjsimonsen/ Binh Nguyen, President: https://www.linkedin.com/in/binh-nguyen-a77046190/ Visit their website:https://www.wynngateconsulting.com/

  7. Jul 28

    Why Yield Isn't King: Analytics & Tech Transfer Lessons with Forge Biologics CTO David Dismuke

    What are the hidden operational mistakes early-stage drug developers make before ever selecting a CDMO? In this episode of Out of the Lab, host Nicholas Crudele sits down with David Dismuke, Chief Technology Officer at Forge Biologics. Drawing on over 20 years of experience across both academic CDMOs, corporate CDMOs, and therapeutic developers, David breaks down why yield should not be your only metric, how host cell DNA and empty/full ratios impact clinical timelines, and why a low-CV potency assay is your ultimate insurance policy during tech transfer. In this episode, we cover: The Yield Trap: Why focusing solely on viral titer masks critical quality attributes (CQAs) that can derail regulatory filings. Empty vs. Full Capsid Ratios: Managing host cell DNA trade-offs and understanding route of administration impacts. Potency Assays as Comparability Anchors: How high-throughput, sound analytical methods allow you to innovate safely in GMP environments. Two-Sided Tech Transfer: Why you should never "throw the process over the wall" and how to execute proper gap analyses with your CDMO. Single-Use Equipment: Navigating downstream chromatography hurdles and eliminating multi-product contact risks.

  8. Jul 28

    The Holy Grail of MES: Why Paperwork Isn't Process Control | Robert Perks

    Why do biomanufacturing execution systems fail despite multi-million dollar investments? In this episode of Out of the Lab, host Nicholas Crudele sits down with biopharma automation and manufacturing execution system (MES) consultant Robert Perks to unpack the realities of digitizing biomanufacturing workflows. From early R&D data integration to navigating the FDA’s shift toward Computer Software Assurance (CSA), Robert shares what it actually takes to achieve release by exception. Key Topics Covered: Cross-Functional Ownership: Why MES implementations fail when controlled by a single department. CSV to CSA Shift: Moving away from binders of paper to risk-based critical thinking. Designing for the Operator: Eliminating duplicated data entry and friction on the cleanroom floor. Bridging R&D and Manufacturing: Leveraging early KPI and CQA data to build standardized Master Batch Records (MBRs). Release by Exception: What infrastructure is required to make automated batch release a reality. Timestamps: 00:00:00 – Introduction & Operational Scope 00:01:14 – What is an MES & Who Needs a Seat at the Table? 00:03:12 – When Should Early Biotechs Engage with MES? 00:07:55 – Operator Optimization & Reducing Data Duplication 00:11:46 – The Regulatory Paradigm Shift: From CSV to CSA 00:18:48 – Integrating R&D Data into Scale-Up Master Batch Records 00:26:44 – The Holy Grail: Achieving Release by Exception

See All (43)

About

In Cell & Gene Therapy, opportunity created by openly discussing operational reality far outweighs the micro-risk of looking unpolished. By building a safe, unscripted space where experts can talk naturally about real work, we stop pretending everything is fine and start building the solutions needed to actually fix the system. Explore our Solution: https://www.methodmade.ca/?utm_source=podcast&utm_medium=show_notes&utm_campaign=out_of_the_lab

Information